Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- WTW +20.6%, BGFV +18.2%, DAR +9.1%, LOW +8.5%, LOGM +7.5%, DY +5.7%, EVH +5.3%, (light volume), MACK +5.2%
- MYL +4.9%, MCHP +4.8%, FOLD +4.8%, MIDD +4.5%, CRH +4.5%, DPLO +4.4%, DLTR +4%, BLDR +3.9%, HLIT +3.7%
- PCRX +3.1%, KERX +2.4%, ODP +2.4%, EVEP +2.3%, BUFF +2.2%, BV +2.2%, TASR +1.9%, NAME +1.5%, WIN +1.5%
- AMC +1.4%, TCON +1.3%, DXCM +1.1%, ORA +1.1%, GTN +1.1%, MNK +1.1%
M&A news:
- CLNE +33.1% ( sells the upstream portion of its renewable natural gas business to BP)
- TIME +9.1% (Bloomberg reporting that five suitors were asked to submit bids next week)
- TRCO +8.9% (said to have been approached by Sinclair Broadcast (SBGI) about a possible combination, according to Reuters; also reported earnings)
Select financial related names showing strength:
- DB +4.1%, CS +3.7%, SAN +2.4%, RBS +2.4%, MS +2.2%, C +2.1%, ING +2%,BAC +2%, GS +2%, WFC +1.5%
Select metals producers trading higher:
- CLF +3.2%, X +3% (also VP/CFO that David Burritt has been elected Pres/COO), VALE +2.7%, BBL +2.3%, BHP +1.5%
Select Gaming related names showing strength following release of Macau gaming revs rising 18% YoiY:
- MPEL +3.8%, WYNN +3.3%, LVS +3.3%, MGM +2.6%
Other news:
- DVAX +28.9% (FDA has accepted for review its responses to the CRL issued by the FDA in November 2016 for the Biologics License Application for HEPLISAV-B; PDUFA action date of August 10, 2017)
- CLSD +14.6% (receives a NOA from the USPTO for methods of treating the posterior ocular disorder Uveitis)
- AGIO +3.7% (Agios Pharma and Celgene (CELG) announce that the FDA has accepted and granted priority review for the NDA for enasidenib)
- LXRX +3.5% (receives FDA approval for XERMELO)
- WLH +3.3% (will replace Arctic Cat in the S&P SmallCap 600)
- PRCX +3.1% (reports 'positive' topline results for phase 4 study of Exparel )
- AMD +2.9% (Advanced Micro and Bethesda Softworks announce partnership)
- OMER +2.5% (presents additional 'positive' data from the ongoing Phase 2 clinical trial evaluating OMS721)
- JKS +2.3% (entered into a Power Purchase Agreement with the Abu Dhabi Water and Electricity Co)
- NVDA +1.8% (released GeForce GTX 1080 Ti)
Analyst comments:
- MU +2.6% (upgraded to Buy from Neutral at Goldman)
- KITE +1% (target raised to $85 at H.C. Wainwright)